Biocon CEO Siddharth Mittal outlines the company's strategy in the competitive GLP-1 market. Focusing on liraglutide's launch in the US and...

Eli Lilly stock today: Eli Lilly achieved a historic milestone, briefly touching a $1 trillion market cap. This success is driven by strong...

At a recent industry summit, executives from Eli Lilly and Novo Nordisk unveiled their game plan for tackling weight-loss medications in In...

Pfizer has agreed to acquire obesity drug developer Metsera for up to $86.25 a share, surpassing Novo Nordisk's final offer. This move mark...

Mounjaro has made a splash in Indian healthcare, emerging as the go-to solution for both diabetes management and weight loss. This remarkab...

Pfizer sued Metsera and Novo Nordisk, alleging Metsera breached its merger agreement by deeming Novo's $8.5 billion bid superior. Pfizer se...

In a bold push for greater influence, a key investor in Novo Nordisk is advocating for a complete overhaul of the board. This strategic man...

Novo Nordisk’s stock has tumbled from record highs after slashing its 2025 outlook, as fierce competition, leadership changes, and legal ch...

Mounjaro, Eli Lilly's weight-loss drug, witnessed a massive sales jump in India since March. Sales reached ₹26 crore in June. Wegovy from N...

Indian drug cos are increasing their presence in the insulin market. They are competing with multinational corporations. Affordable insulin...

Pfizer halted development of its weight-loss pill, danuglipron, after liver injury concerns surfaced during trials, impacting its ambition ...

“In Sun-Taro’s case, they pushed up the price because there was not much competition or suppliers.”

Insulin brands are set to appeal against the drug price regulator's decision to further squeeze their profit margins on the diabetes medici...

"Any partner who looks at this asset will back-load the payment because while the market is huge, we still don't know if the drug works the...

American firm Abbott Laboratories consolidated its top position in the Indian drug retail market by growing at a faster than its closest co...

The Bangalore-based firm’s scrip opened at Rs 445, reached an intra-day high of Rs 464.6 before closing at Rs 455, up 12.97% over Monday’s ...

The agreement includes the commercialisation of Biocon’s biosimilar versions of insulin and insulin analog products: recombinant human insu...